Nanjing Pharmaceutical

Nanjing Pharmaceutical Group Company Limited reports **CNY 41.7 billion in sales** and **CNY 415.2 million in net income** for the nine months ended September 30, 2026. Sales grew **CNY 551.8 million year-over-year**, while net income increased **CNY 13.25 million** compared to the same period in 2025. The company’s financial performance reflects steady revenue and profitability growth in its core pharmaceutical operations.

Oct 2026MarketScreenerNews article

Nanjing Pharmaceutical acquires majority stakes in **Datsing Bio-Tech** (44.95%) and **Kejian Technology** (50.98%) through its investment fund for **RMB 750 million**. The deal expands Nanjing Pharmaceutical’s presence in biotech and technology sectors. Both acquired companies operate in Beijing. The transaction reflects strategic growth in pharmaceutical and life sciences investments.

Jul 2026Insight, China's Pharmaceutical IndustryNews article

Nanjing Pharmaceutical Group Co. establishes a **$110 million corporate fund** to acquire controlling stakes in **Beijing Datsing Biotechnology** and **Beijing Kejian Technology**. The fund, totaling **RMB 450 million**, supports Nanjing Pharma’s vertical integration strategy in medical technology. The company targets minority ownership in two Chinese biotech firms to expand its capabilities.

Apr 2026Insight, China's Pharmaceutical IndustryNews article

Nanjing Pharmaceutical Co. removes two directors and dismisses one vice president nominated by its former major shareholder, Alliance Healthcare, following its complete exit. The company also nominates executives from Guangzhou Pharmaceutical Group to fill leadership roles. Luo Xunjie, one of the removed directors, abstained from voting on the proposals.

Mar 2026BigGo FinanceNews article